Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis

Documenti analoghi

• Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors
  di: Anat Tsur, et al.
  Pubblicazione: (2025)
• Risk of recurrent diabetic ketoacidosis following initiation of sodium‐glucose co‐transporter 2 inhibitors in patients with an insulin‐deficient diabetes and prior diabetic ketoacidosis: An observational cohort study
  di: Anat Tsur, et al.
  Pubblicazione: (2026)
• Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
  di: Chi‐Ho Lee, et al.
  Pubblicazione: (2024)
• Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study
  di: Yun Wang, et al.
  Pubblicazione: (2025)
• SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany
  di: Theresia Sarabhai, et al.
  Pubblicazione: (2025)